The Arora Report

Rss Facebook Twitter Linkedin

Stock Market News To Give You An Edge

Proven Track Record of Most Accurate Analysis

Stock Market News
To Give You An Edge​

Proven Track Record
of Most Accurate Analysis

COMPLETELY INDEPENDENT AND OBJECTIVE

The Arora Report, Ltd. is a rare publisher that does not accept advertisements. This way The Arora Report can not be influenced. The Arora Report also does not accept payments from any company that is the subject of the posts. The Arora Report has forsaken millions of dollars in revenues to avoid conflicts of interest. Our sole job is to help you. Read more.

COMPLETELY INDEPENDENT AND OBJECTIVE

The Arora Report, Ltd. is a rare publisher that does not accept advertisements. This way The Arora Report can not be influenced. The Arora Report also does not accept payments from any company that is the subject of the posts. The Arora Report has forsaken millions of dollars in revenues to avoid conflicts of interest. Our sole job is to help you. Read more.

MOMENTA PHARMACEUTICALS JUMPS ON COPAXONE RULING, TAKE PROFITS AND EXIT THE POSITION IF STILL HOLDING $MNTA $MYL $TEVA

February 2, 2017

This post was published on ZYX Buy Change Alert. MNTA has an average price of $11.31.  As of this writing it is trading at $19.05. The stock has jumped on a court invalidating TEVA patent on a MS drug Copaxone.  This was part of the original thesis to buy MNTA.  MYL is the other beneficiary. The stock previously hit the target zone but not the upper band of the target zone until yesterday.  It appears that many subscribers are still holding. Consider taking profits on the position, if still holding, in the zone of $18.43 to $20.88 and exit the position.  As

Read More »

MYLAN BENEFITING FROM COPAXONE $MYL $TEVA

February 1, 2017

This post was just published on ZYX Buy Change Alert. MYL is benefiting from invalidation of TEVA patent on Copaxone, an MS drug.  The new buy zone is $32 to $35.57.  Recommended position size is 35% to 40%.  The stock is trading at $38.40 as of this writing. What To Do Now Those in the stock may continue to hold. Those not in the stock may consider waiting for a dip into the buy zone. You are receiving less than 2% of the content from our paid services …TO RECEIVE REMAINING 98%, TAKE A FREE TRIAL TO PAID SERVICES. Please click here

Read More »

UPDATE ON RITE AID BUYOUT BY WALGREENS BOOTS $RAD $WBA $FRED

January 30, 2017

This post was just published on ZYX Buy Change Alert.  Totally contrary to its prior statements, WBA has reduced the buyout price for RAD from $9 per share to $7 per share if fewer than 1000 stores are required to be divested and to $6.50 if 1200 stores are required for divesture.  If divesture falls between 1000 and 1200 stores, there will be a pro-rata adjustment.  The date of the agreement has been extended to July 31, 2017. There are two separate and distinct RAD positions. What To Do Now The long-term position is from $4.95.  Profits have been taken on all but

Read More »

A NEW TRADE AROUND POSITION ON RITE AID $RAD $WBA $FRED

January 27, 2017

This post was just published on ZYX Buy Change Alert. This is a short-term trade, not an investment for aggressive traders as the risk of loss is high. Consider buying up to 20% of RAD in the zone of $6.00 to $6.70.  Stop zone is $5.38 to $5.73.  Target zone is $7.50 to $8.75. Caution: this is not suitable for conservative investors. Please see Trade Management Guidelines to learn about Trade Around Positons.  This is separate and distinct from the long-term RAD position. You are receiving less than 2% of the content from our paid services …TO RECEIVE REMAINING 98%, TAKE A

Read More »

WEEKLY MARKET DIGEST: GROWTH COOLS, CUSP OF TRADE WAR, GOLD INVESTORS WATCH JAPANESE AND FRENCH BONDS $DIA $GLD $QQQ $SLV $SPY $TBF $TBT $USO

January 27, 2017

   Weekly Digest from The Arora Report is popular among serious investors and money managers because they have found studying insights from the prior week gives them an edge over the coming weeks. Here is the day by day rundown from the morning capsules made available every morning before the market open in the Real Time Feeds to the paying subscribers of The Arora Report.  Please scroll down for the section What To Do Now. GROWTH COOLS, GOLD UNDER PRESSURE BUT STILL IN SUPPORT ZONE, CUSP OF TRADE WAR WITH MEXICO January 27, 2017 This is what you need to

Read More »

NIGAM ARORA ON GOLD: IF TRUMP’S REMARKS CAUSE CURRENCY TURMOIL, GOLD WILL GO UP $GLD $SLV $NUGT $ABX $CDE $DUST $GDX $GDXJ $HMY $SLW

January 26, 2017

Here is the interview of Nigam Arora on gold by Business Standard, India’s second largest financial publication.  India is often the largest or the second largest consumer of gold.  Enjoy! Nigam Arora is a financial market expert forecasting market trends using algorithms. His famous ‘Arora report’ is widely followed. In an interview to Rajesh Bhayani he explains why in medium term gold looks weak. Edited excerpts: Gold prices have risen from its November lows. Why and what is your outlook in near and medium term? There have been three reasons behind gold’s up move. First there are whiffs of inflation

Read More »

CONGRATULATIONS TO THOSE WHO FOLLOWED US ON ACTELION , $70+ ON 121ST BUYOUT, 289.76%+ ANNUALIZED RETURN, BUYER IS JOHNSON & JOHNSON $ALIOY $JNJ

January 26, 2017

This post was just published on ZYX Buy Change Alert.  Only 62 days ago our call was to buy ALIOY on a potential buyout.  Average price is $45.57.  This is the 121st buyout of our portfolio companies. Over the years, the long-time subscribers to The Arora Report have generated substantial wealth from so many of our portfolio companies getting bought out producing handsome profits. The buyout by JNJ is for $70 cash plus the holders will get shares in a new company that will contain R&D efforts of Europe’s largest biotech. The 289.76% annualized return  is calculated on $68 per share where the stock is

Read More »

A NEW IDEA ON SEAGATE TECHNOLOGY $STX $WDC $MU

January 26, 2017

This post was published on ZYX Buy Change Alert. STX is a computer storage manufacturer. Of note is that the company has 6.93% dividend yield and the yield will be much higher if bought in the proposed buy zone.  The company reported earnings significantly better than the whisper numbers.  As we were writing  a post giving you this new idea, the stock jumped making it imprudent to buy at that time.  This morning the stock has continued to go higher reaching as high as $46.68.  As of this writing it has pulled back to $45.15. The plan is to patiently wait for a further

Read More »

AI is power hungry. Investors will make a fortune from nuclear power for AI.
Get the list of 12 nuclear power stocks to grab your share of the profits.

AI is power hungry. Investors will make a fortune from nuclear power for AI.

Get the list of 12 nuclear power stocks to grab your share of the profits.

Big Tech is investing billions

Making A Fortune
In Nuclear Energy

Golden Age of Nuclear Energy

Skip to content